 CRANBURY, N.J., Sept. 29, 2021 PRNewswire -- Palatin Technologies, Inc., NYSE American: PTN, a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced results for its fourth quarter and fiscal year ended June 30, 2021. 